IntroDuctIon
Despite over 25 years of research since the identification of HIV as the causative agent of AIDS, the correlates of protection necessary for an effective prophylactic HIV vaccine remain elusive. Indeed, the failure of the Merck STEP trial underscores the need to understand the events of the viral replication cycle and antiviral immune response in greater detail. To this end, the development of new techniques is a necessary step to facilitate discoveries and insights into how best to overcome HIV's subversion of the immune system. One such technique is magnetofection, which results in a synchronized infection in vitro.
Magnetofection is a generic term applied to the method of using magnetic force to bring vectors, such as nucleic acids, into close proximity to target cells. Indeed, the most widely used applications of this method are DNA transfection and siRNA gene silencing 1, 2 . Recently, however, several groups have begun to apply the magnetofection technique to HIV research [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . In this application of magnetofection, HIV or SIV virons are first rendered magnetically active by electrostatic associations of the viral Envelope protein with cationic ferrous nanoparticles. Next, a magnetic field is used to direct the magnetized virions to the surface of the target cell, thus overcoming the rate-limiting step of infection, which is the initial virus-cell interaction 11, 14 . A major benefit of this technique is that infecting virions attach to target cells within minutes of the addition of a magnetic field, thus synchronizing the infection at the attachment step of the viral replication cycle.
The synchronization of HIV infection in vitro allows investigators to study events in, and the cellular response to, the viral replication cycle on extremely small and precise timelines. Indeed, this technique has recently been successfully used to investigate the kinetics of SIV peptide epitope presentation to CD8 + 4, 5, 7 and CD4 + T cells 6 , define conformational state dynamics of HIV Env 12 and determine a new parameter to measure the efficiency of neutralizing antibodies 13 . Furthermore, because a large percentage of cells are infected in a short amount of time, magnetofection can increase the throughput of in vitro T cell assays which require virally infected cells 3, 9, 10, 15 .
Comparison with spinoculation
The HIV replication cycle initiates when the virion encounters and binds the CD4 molecule on a target cell with the viral Env glycoprotein gp120/41. Owing to the colloidal nature of cell-free virus particles in suspension, the diffusion-dependent step of virus-cell interaction is extremely inefficient and is, thus, the rate-limiting step in the replication cycle. For example, in a traditional in vitro infection technique, where target cells are incubated with virus for multiple hours in a small volume, only a fraction of viruses ever come into contact with cells and, thus, just a small percentage of cells become infected. Infection techniques that increase the efficiency of the initial attachment step by bringing virus particles into contact with target cells, therefore, result in higher levels of infection. Spinoculation, which uses centrifugal force 16 , and magnetofection, which uses magnetic force 14 , both increase infection efficiency by concentrating infectious virions onto target cells. Indeed, both methods result in similar levels of infected primary CD4 + T cells (Fig. 1a) . Furthermore, cells infected with either method behave in a similar manner and efficiently process and present Gag peptide epitopes to Gag-specific CD8 + T cells (Fig. 1b) .
Although similar levels of infection are achieved with both techniques, magnetofection has two major advantages over spinoculation. First, the spinoculation technique is time intensive, as cells must be centrifuged with virus for 2 h, followed by another incubation at 37 °C to allow viral fusion. In contrast, magnetofection is extremely rapid with incubation times as short as 1 min sufficient for sedimentation of virions onto target cells 14 . Second, because spinoculation requires a 2-h initial incubation time of virus with cells, the infection is not truly synchronized. Although this is not necessary for many in vitro applications, this precludes the use of spinoculation for experiments examining the kinetics of events in the viral replication cycle in precise detail 5, 12, 13 . Therefore, magnetofection is the only method currently available that results in a synchronized infection.
Limitations and applications of magnetofection
One major limitation of magnetofection is the residual presence of a small amount of magnetic nanoparticles following infection.
Synchronous infection of SIV and HIV in vitro for virology, immunology and vaccine-related studies the development of an HIV vaccine will require a more precise understanding of the immunological and virological underpinnings of HIV infection. Magnetofection, the process of magnetizing HIV by coupling it to ferrous nanoparticles and coordinating infection using a magnetic field, synchronizes the viral replication cycle at attachment while recapitulating the events of natural infection. although spinoculation also concentrates virus onto target cells to increase infection, it does not synchronize infection. the synchronization of HIV infection in vitro facilitates the study of events in the viral replication cycle and the antiviral immune response on timelines previously impossible. Furthermore, by infecting a high percentage of cells in a short time frame, magnetofection increases the throughput of in vitro assays. once a virus stock is generated, magnetofection of target cells is rapid, requiring only 1-2 h. Here we present a detailed protocol for this assay and review its applications for studying the immune response to HIV. Although we have encountered no problems in downstream applications of cells following magnetofection, the possibility exists that the presence of residual nanoparticles may interfere with very sensitive techniques. Furthermore, depending on the amount of virus used, magnetofection could result in super-physiological amounts of virus entering target cells. Therefore, it is highly recommended that a virus titration be carried out to exclude this possibility and extend the results to physiological levels as described elsewhere 4 . The ability to synchronously direct the attachment of viral particles to target cells is a valuable tool in investigations of the viral replication cycle. For example, we have successfully used the technique to pinpoint the exact time required for CD8 + and CD4 + T-cell epitopes to reach the cell surface and be presented by the MHC molecule to T cells [4] [5] [6] [7] . Furthermore, synchronous infections allow detailed investigations of the virus itself. Indeed, the technique has been used to study short-lived conformational states of the Envelope protein 12 . These studies are important in understanding the mechanism of HIV entry inhibitors and neutralizing antibodies. Magnetofection, therefore, can be used to study the critical events in the virus replication cycle on a time frame not possible with other infection methods.
Experimental design
Virus stocks and target cells. There are two main components of this method that must be prepared before beginning the assay. As shown in the experimental overview for magnetofection, they are the virus stock (Fig. 2a) and the target cells (Fig. 2b) .
Many laboratory-adapted and laboratoryisolated HIV and SIV virus variants are available as provirus-containing plasmids from reagent programs such as the NIH AIDS Research and Reference Reagent Program. Protocols to isolate and propagate clinical isolates of HIV are described elsewhere 17 . The optimal choice of virus depends on the experimental parameter being investigated and should be chosen accordingly. nitrogen. Using this method, a large-scale, high-titer virus stock of upto 1 liter can be produced. Once aliquoted and stored in liquid nitrogen, these virus stocks are viable with no loss of infectivity for upto 5 years as described elsewhere 17 . Because of the long-term stability of frozen virus stocks, this step can be carried out at any time at least 2 weeks before carrying out magnetofection.
The choice of target cells is also dependent on the exact research parameter being investigated. Indeed, magnetofection has been used to infect primary CD4 + T cells 4 , monocyte-derived macrophages 6 and immortalized CD4 + T-cell clones 8 . Because primary CD4 + T cells are the most broadly applicable and physiologically relevant cell type for in vitro assays, we will focus on the generation of these cells in this protocol (Fig. 2b) . Infection of other cell types is carried out exactly as described here. Furthermore, CD4 + T cell targets isolated and activated according to this protocol will propagate for up to a month in culture. Therefore, CD4 + T cell targets can be isolated and activated anywhere from the day before to 1 month before carrying out magnetofection. However, depending on whether activated or resting CD4 + T cells are desired as targets will ultimately determine when the cells are used post activation.
Once the virus stock ( Fig. 2a) and target cells (Fig. 2b) are prepared, magnetofection can be carried out. First, the virus stock is purified by centrifugation over a 20% sucrose cushion in a tabletop microcentrifuge (Fig. 2c) . This results in a very pure and concentrated virus solution for infection. Next, the purified virus is incubated with the magnetic nanoparticles for 15 min and then brought into contact with the target cells via magnetic force (Fig. 2d) . As a negative control, target cells should be incubated with magnetic nanoparticles alone.
MaterIals

REagEnts
ViroMag It is recommended that work with these plasmids be conducted in a biosafety level 2 plus facility following level 2 plus safety measures. Biosafety level 2 plus requires, at minimum, the use of a biosafety level 2 facility with containment equipment, training, planning and practices of a biosafety level 3. Thus, the work described in this protocol should be carried out under the guidelines of a biosafety level 2 plus laboratory. All waste should be
• considered infectious and thus autoclaved and liquid waste should be inactivated with bleach. sEB Resuspend lyophilized SEB to 500 µg ml − 1 using 2 ml of 1× PBS and divide into 20 µl aliquots. Can be stored at − 20 °C for up to 1 year. IL-2 Resuspend lyophilized IL-2 to 500,000 IU ml − 1 in sterile 1× PBS and freeze in 50 µl aliquots. Resuspended IL-2 can be stored at − 20 °C for up to 1 year. R10 media To 500 ml RPMI, add 55 ml FCS, 5.5 ml L-glutamine and 5.5 ml antibiotic/antimycotic. Sterile filter using vacuum filter flask. Can be stored at 4 °C for up to 3 weeks. R15 media To 124 ml RPMI, add 22.5 ml FCS, 1.5 ml L-glutamine and 1.5 ml antibiotic/antimycotic. Sterile filter using vacuum filter flask. Can be stored at 4 °C for up to 3 weeks. R15-100 media Add 10 µl IL-2 to 50 ml R15 media. Can be stored at 4 °C for up to 1 week. 1× aCK Prepare a 20× ACK stock by adding 82.9 g NH 4 Cl, 10 g KCO 3 and 4.2 g NA 2 EDTA to 500 ml ddH20. The 20× ACK stock is stabile for up to a year at room temperature (20-25 °C). Prepare 1× ACK by adding 25 ml 20× ACK to 475 ml ddH20 and sterile filter. 1× ACK can be stored for up to 1 year at room temperature. 4| Add the DNA-lipofectamine mixture to the vero cells drop wise, distributing the drops all over the surface of the well. Rock the plate gently to mix.  crItIcal step Do not swirl to mix as this may concentrate the transfection reagent in the middle of the wells and lead to toxicity of the cells.
5|
Incubate transected vero cells overnight in humidified incubator at 37 °C.
6| Centrifuge 2 × 10
6 CEMx174 cells for 8 min at 500g at room temperature to pellet. Decant supernatant and resuspend CEMx174 cells in 4 ml R10 media.
7|
Remove culture supernatant from virus-producing vero cells and add the 4 ml of R10 media containing the CEMx174 cells.
8| Incubate cells for 24 h in humidified incubator at 37 °C to initiate infection of CEMx174 cells.
9| Add 3 ml of R10 media to feed cells. Incubate the cells for 24 h in humidified incubator at 37 °C.
10|
Collect the culture supernatant containing the CEMx174 cells using a 5 ml pipette. Tilt the plate and slowly wash the vero cells to dislodge any CEMx174 cells that might be stuck.  crItIcal step Be careful not to dislodge vero cells.
11|
Transfer CEMx174 cells to a T75 flask and add 14 ml R10 media. Total culture volume should now be 21 ml. Incubate 48 h in humidified incubator at 37 °C.
12|
Feed cells by adding 25 ml of R10 media, bringing total volume to 46 ml. Incubate 48 h in humidified incubator at 37 °C.
13|
Resuspend CEMx174 cells and remove and discard 23 ml culture. Add 23 ml fresh R10 media. Incubate 48 h in humidified incubator at 37 °C.
14|
Resuspend CEMx174 cells and remove 23 ml culture. If a larger volume of virus stock is desired, then transfer the freshly harvested 23 ml of CEMx174-containing media to a new T75 to expand the culture. Otherwise, simply discard the freshly harvested 23 ml of CEMx174-containing media. Add 23 ml fresh R10 media to bring T75 flask(s) to feed cells. Incubate 48 h in humidified incubator at 37 °C.
15|
To harvest the virus-containing supernatant, resuspend the cells and transfer culture to 50 ml conical tubes and centrifuge for 8 min at 500g at room temperature to pellet cells.
16|
Pool cell-free supernatants and filter through 0.22 µm filter flask. Aliquot filtered supernatant into 1.8 ml cryotubes (aliquots of 1 ml) and store in liquid nitrogen freezer.
17|
Resuspend CEMx174 cells in fresh R10 media to original culture volume, return to T75 flask and incubate 48 h in humidified incubator at 37 °C.
18|
Transfer culture to 50 ml conical tubes and centrifuge for 8 min at 500g at room temperature to pellet cells. 19| Pool cell-free supernatants and filter through 0.22 µm filter flask. Aliquot filtered supernatant into 1.8 ml cryotubes (aliquots of 1 ml) and store in liquid nitrogen freezer.  pause poInt Virus can be stored in liquid nitrogen for upto 10 years without significant loss of infectivity.
20|
Test one aliquot from each harvest for vRNA copy number in QRT-PCR as described in detail elsewhere 18 . ? trouBlesHootInG Isolation and activation of cD4 + t cell targets • tIMInG 4-6 h 21| Slowly layer anticoagulant-treated blood on top of 5 ml of Ficoll-Paque in a 15 ml conical tube.
22|
Centrifuge for 30 min at 1,000g at room temperature with the centrifuge brake off.
23|
Collect the band of cells that sits directly on top of the Ficoll layer with a transfer pipette and transfer to a new 15 ml conical tube. Fill conical to 15 ml with 1× PBS. Centrifuge for 8 min at 500g at room temperature.
24|
Decant supernatant and resuspend cell pellet in 5 mls of 1× ACK buffer. Incubate at room temperature for 5 min to lyse residual red blood cells. Fill tube to 15 ml with 1× PBS to stop reaction. Centrifuge for 8 min at 500g at room temperature.
25|
Decant supernatant and resuspend cells in R10 media. Count cells using an automated cell counter or trypan blue and a hemacytometer.  pause poInt PBMC in R10 media can be incubated in a vented T25 or T75 flask in humidified incubator at 37 °C for upto 4 d.
26|
Isolate CD4 + T cells using the Miltenyi CD4 + T-cell microbead enrichment kit according to the manufacturer's instructions. 
32|
Aliquot 100 µl of 20% sucrose solution into Sarstedt microcentrifuge tube.
33|
Carefully layer 1 ml of virus stock onto the sucrose. Upto 1.2 ml of virus stock can safely be layered onto sucrose solution. (Using 1 ml of virus stock is meant only to provide a starting point. Each virus stock should be titrated to determine the optimal level of virus per experimental needs. To this end, carry out a titration of the amount of infecting virus used. For example, infect a fixed number of cells with tenfold dilutions of sucrosepurified virus. Monitor infection efficiency via intracellular Gag p27 staining to determine virus needed for experimental purposes). The effects of sucrose purification can be seen in Figure 3 .  crItIcal step Mixing of the virus with sucrose will result in inefficient purification of the virus and thus lower levels of infection. Refer to Figure 3 for the importance of the purification step.
34|
Centrifuge in microcentrifuge for 1 h at 20,000g at 4 °C.
35|
Carefully aspirate all of the culture supernatant sitting on top of the sucrose solution.  crItIcal step Residual culture supernatant will reduce infection efficiency.
36|
Resuspend virus-containing sucrose solution with 100 µl cold R10 media. Pipette up and down to mix.
Magnetofection of activated cD4 + t cells
• tIMInG 1 h 37| Vortex ViroMag beads and add 10 µl of ViroMag (VM) beads to the virus-containing sucrose. Pipette up and down to mix. (Although 10 µl of VM beads is a good starting point and is sufficient to bind up to 3 × 10 8 viral particles, the optimal ratio of virus to VM beads should be determined for each virus stock, amount of virus and cell type. Carry out infections using a fixed amount of cells and virus incubated with varying amounts (i.e., 1-20 µl) of VM beads to determine optimal ratio.) For mock infection, add VM beads to 100 µl cold R10.
38|
Incubate at room temperature for 15 min.
39|
While the virus is undergoing incubation, count the target CD4 + T cells using an automated counter or trypan blue exclusion. Place between 1 × 10 6 and 2 × 10 6 in a well of a 24-well plate. Although the volume does not affect infection efficiency, allow enough volume for addition of virus-VM bead mixture.
40|
Add virus-VM bead mixture to target CD4 + T cells and pipette to mix. Centrifuge for 2 min at 500g at room temperature to pellet cells.
41|
Carefully remove plate and place on ViroMag magnetic plate. 
antIcIpateD results
The process described here will result in a synchronous infection of a large percentage of target cells in vitro for downstream applications. For instance, these cells can be used as antigen presenting cells to study epitope presentation to T cells or be examined directly for events in the viral replication cycle, such as Nef-mediated MHC-I downregulation. It is important to note that as the infection is synchronized at the step of attachment of the virion to the cell, the infected cells are ready for use directly following the end of this protocol. Immediately following magnetofection, the infected population can be visualized, e.g., by staining for intracellular HIV/SIV Gag p27 CA . As shown in Figure 4 , the infected cells are initially located within the CD4 + , Gag p27 + gate because of the presence of Gag proteins from the infecting virion in the cell cytoplasm. By 24 h post-infection, a distinct population of productively infected cells is detectable in the CD4 − , Gag p27 + gate. The cells can be cultured upto an additional 48 h per assay needs and, importantly, the percentage of infected cells will increase as each synchronized wave of progeny virions is produced and released. 
